B-cell memory against factor VIII.
Austria. In Cell Immunol, Feb 2016
UNASSIGNED: The development of persistent neutralizing antibodies against factor VIII (FVIII) is the most severe complication in the treatment of congenital hemophilia A patients with FVIII replacement therapies.
Developments in the diagnostic procedures of von Willebrand disease.
Leiden, Netherlands. In J Thromb Haemost, Jan 2016
These bleeding episodes are all related to quantitative or qualitative defects of von Willebrand factor (VWF), a multimeric glycoprotein produced by endothelial cells and megakaryocytes, which mediates platelet adhesion and aggregation and binds factor VIII (FVIII) in the circulation.
Immunogenicity of long-lasting recombinant factor VIII products.
Paris, France. In Cell Immunol, Jan 2016
UNASSIGNED: Replacement therapy for patients with hemophilia A using plasma-derived or recombinant factor VIII (FVIII) is complicated by the short half-life of the FVIII products and by the occurrence of neutralizing antibodies in a substantial number of patients.
Acquired haemophilia: an overview for clinical practice.
Washington, D.C., United States. In Eur J Haematol, Dec 2015
Diagnosis involves an isolated prolongation of the activated partial thromboplastin time, without correction in mixing studies, low FVIII activity levels and evidence of a FVIII inhibitor.
Factor VIII products and inhibitor development in severe hemophilia A.
Utrecht, Netherlands. In N Engl J Med, 2013
BACKGROUND: For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development).